BRIEF—Eisai's new facility in China comes online

Japan’s Eisai has commenced full-scale operation of its new Suzhou, China-based plant. The facility is around five times larger than the former plant, and will be used to manufacture oral solid dose products.

The site will handle the formulation and packaging of products such as Methycobal, Aricept and Pariet for the domestic Chinese market.

The firm says it is seeking to “strengthen its in-house domestic production system in China and expand its stable supply chain of high quality pharmaceuticals.”